JP2019512493A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019512493A5 JP2019512493A5 JP2018548192A JP2018548192A JP2019512493A5 JP 2019512493 A5 JP2019512493 A5 JP 2019512493A5 JP 2018548192 A JP2018548192 A JP 2018548192A JP 2018548192 A JP2018548192 A JP 2018548192A JP 2019512493 A5 JP2019512493 A5 JP 2019512493A5
- Authority
- JP
- Japan
- Prior art keywords
- humanized antibody
- human
- composition
- seq
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 claims description 90
- 208000024908 graft versus host disease Diseases 0.000 claims description 55
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 53
- 238000001802 infusion Methods 0.000 claims description 35
- 230000000735 allogeneic effect Effects 0.000 claims description 26
- 230000001154 acute effect Effects 0.000 claims description 21
- 150000001413 amino acids Chemical class 0.000 claims description 20
- 239000000427 antigen Substances 0.000 claims description 19
- 102000036639 antigens Human genes 0.000 claims description 19
- 108091007433 antigens Proteins 0.000 claims description 19
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 19
- 102000006495 integrins Human genes 0.000 claims description 15
- 108010044426 integrins Proteins 0.000 claims description 15
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 201000011510 cancer Diseases 0.000 claims description 13
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 12
- 238000001990 intravenous administration Methods 0.000 claims description 12
- 229960000485 methotrexate Drugs 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 11
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 10
- 150000003431 steroids Chemical class 0.000 claims description 10
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 claims description 9
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 8
- 239000000090 biomarker Substances 0.000 claims description 8
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 8
- 229960001967 tacrolimus Drugs 0.000 claims description 8
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims description 8
- 230000003750 conditioning effect Effects 0.000 claims description 7
- 208000024340 acute graft versus host disease Diseases 0.000 claims description 6
- 208000026278 immune system disease Diseases 0.000 claims description 6
- 208000032839 leukemia Diseases 0.000 claims description 6
- 239000012931 lyophilized formulation Substances 0.000 claims description 6
- 229960004914 vedolizumab Drugs 0.000 claims description 6
- 208000019838 Blood disease Diseases 0.000 claims description 5
- 210000001185 bone marrow Anatomy 0.000 claims description 5
- 208000014951 hematologic disease Diseases 0.000 claims description 5
- 208000018706 hematopoietic system disease Diseases 0.000 claims description 5
- 230000003211 malignant effect Effects 0.000 claims description 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 4
- 229940122739 Calcineurin inhibitor Drugs 0.000 claims description 4
- 102100024123 Calcineurin-binding protein cabin-1 Human genes 0.000 claims description 4
- 101710192106 Calcineurin-binding protein cabin-1 Proteins 0.000 claims description 4
- 102000013691 Interleukin-17 Human genes 0.000 claims description 4
- 108050003558 Interleukin-17 Proteins 0.000 claims description 4
- 102000004889 Interleukin-6 Human genes 0.000 claims description 4
- 108090001005 Interleukin-6 Proteins 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 229940109239 creatinine Drugs 0.000 claims description 4
- 210000000987 immune system Anatomy 0.000 claims description 4
- 229940100601 interleukin-6 Drugs 0.000 claims description 4
- 230000000968 intestinal effect Effects 0.000 claims description 4
- 210000000265 leukocyte Anatomy 0.000 claims description 4
- 210000003071 memory t lymphocyte Anatomy 0.000 claims description 4
- 230000001400 myeloablative effect Effects 0.000 claims description 4
- 201000005787 hematologic cancer Diseases 0.000 claims description 3
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 3
- 208000028774 intestinal disease Diseases 0.000 claims description 3
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 208000018240 Bone Marrow Failure disease Diseases 0.000 claims description 2
- 208000005623 Carcinogenesis Diseases 0.000 claims description 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 2
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 208000014905 bone marrow failure syndrome Diseases 0.000 claims description 2
- 230000036952 cancer formation Effects 0.000 claims description 2
- 231100000504 carcinogenesis Toxicity 0.000 claims description 2
- 230000001186 cumulative effect Effects 0.000 claims description 2
- 239000012636 effector Substances 0.000 claims description 2
- 208000034737 hemoglobinopathy Diseases 0.000 claims description 2
- 230000028993 immune response Effects 0.000 claims description 2
- 230000001506 immunosuppresive effect Effects 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 210000000440 neutrophil Anatomy 0.000 claims description 2
- 210000005259 peripheral blood Anatomy 0.000 claims description 2
- 239000011886 peripheral blood Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 47
- 230000002265 prevention Effects 0.000 claims 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 208000018337 inherited hemoglobinopathy Diseases 0.000 claims 1
- 239000005557 antagonist Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022092849A JP2022137024A (ja) | 2016-03-14 | 2022-06-08 | 移植片対宿主病の処置または予防の方法 |
| JP2025065073A JP2025118642A (ja) | 2016-03-14 | 2025-04-10 | 移植片対宿主病の処置または予防の方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662307896P | 2016-03-14 | 2016-03-14 | |
| US62/307,896 | 2016-03-14 | ||
| US201662420825P | 2016-11-11 | 2016-11-11 | |
| US62/420,825 | 2016-11-11 | ||
| PCT/US2017/022067 WO2017160700A1 (en) | 2016-03-14 | 2017-03-13 | Methods of treating or preventing graft versus host disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022092849A Division JP2022137024A (ja) | 2016-03-14 | 2022-06-08 | 移植片対宿主病の処置または予防の方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019512493A JP2019512493A (ja) | 2019-05-16 |
| JP2019512493A5 true JP2019512493A5 (https=) | 2020-05-14 |
Family
ID=58455657
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018548192A Withdrawn JP2019512493A (ja) | 2016-03-14 | 2017-03-13 | 移植片対宿主病の処置または予防の方法 |
| JP2022092849A Pending JP2022137024A (ja) | 2016-03-14 | 2022-06-08 | 移植片対宿主病の処置または予防の方法 |
| JP2025065073A Pending JP2025118642A (ja) | 2016-03-14 | 2025-04-10 | 移植片対宿主病の処置または予防の方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022092849A Pending JP2022137024A (ja) | 2016-03-14 | 2022-06-08 | 移植片対宿主病の処置または予防の方法 |
| JP2025065073A Pending JP2025118642A (ja) | 2016-03-14 | 2025-04-10 | 移植片対宿主病の処置または予防の方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20190077868A1 (https=) |
| EP (1) | EP3430053A1 (https=) |
| JP (3) | JP2019512493A (https=) |
| KR (2) | KR102667332B1 (https=) |
| CN (2) | CN117298268A (https=) |
| AU (2) | AU2017234010B2 (https=) |
| BR (1) | BR112018068625A2 (https=) |
| CA (1) | CA3017758A1 (https=) |
| IL (1) | IL261767A (https=) |
| MA (1) | MA43755A (https=) |
| MX (2) | MX2018011025A (https=) |
| WO (1) | WO2017160700A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL261750B2 (en) * | 2016-03-14 | 2024-07-01 | Millennium Pharm Inc | Method of preventing graft versus host disease |
| CN109414502A (zh) | 2016-06-12 | 2019-03-01 | 千禧制药公司 | 治疗炎症性肠病的方法 |
| BR112019022268A2 (pt) * | 2017-04-28 | 2020-05-19 | Millennium Pharmaceuticals, Inc. | método para o tratamento de distúrbios pediátricos |
| WO2024249568A1 (en) | 2023-05-30 | 2024-12-05 | Paragon Therapeutics, Inc. | Alpha4beta7 integrin antibody compositions and methods of use |
| CN121889424A (zh) | 2023-08-14 | 2026-04-17 | 派拉冈医疗公司 | α4β7整联蛋白结合蛋白及使用方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| JP3095168B2 (ja) | 1988-02-05 | 2000-10-03 | エル． モリソン，シェリー | ドメイン‐変性不変部を有する抗体 |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US5840299A (en) | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| US7803904B2 (en) | 1995-09-01 | 2010-09-28 | Millennium Pharmaceuticals, Inc. | Mucosal vascular addressing and uses thereof |
| EP0808367B1 (en) | 1995-02-10 | 2007-07-11 | Millennium Pharmaceuticals, Inc. | Mucosal vascular addressins and uses thereof |
| US7147851B1 (en) * | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
| US20010046496A1 (en) | 2000-04-14 | 2001-11-29 | Brettman Lee R. | Method of administering an antibody |
| EP2399903A1 (en) | 2002-05-24 | 2011-12-28 | Millennium Pharmaceuticals, Inc. | Ccr9 inhibitors and methods of use thereof |
| US6939885B2 (en) | 2002-11-18 | 2005-09-06 | Chemocentryx | Aryl sulfonamides |
| MX350383B (es) | 2004-01-09 | 2017-09-04 | Pfizer | Anticuerpos contra madcam. |
| RS52213B (sr) | 2004-09-03 | 2012-10-31 | Genentech, Inc. | Humanizovani anti-beta7 antagonisti i njihove primene |
| CA2624524C (en) * | 2005-09-29 | 2014-07-08 | Elan Pharmaceuticals, Inc. | Carbamate compounds which inhibit leukocyte adhesion mediated by vla-4 |
| JP2009515552A (ja) | 2005-11-17 | 2009-04-16 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | α４β７インテグリン反応性ヒト化免疫グロブリン |
| CN103382222B (zh) | 2009-03-20 | 2016-12-28 | 安姆根有限公司 | α-4-β-7异二聚体特异性拮抗剂抗体 |
| UA116189C2 (uk) * | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| DK3311834T3 (da) | 2011-05-02 | 2026-04-20 | Millennium Pharmaceuticals Inc | Formulering til anti-alfa4beta7-antistof |
| MA41636A (fr) * | 2015-03-06 | 2018-01-09 | Millennium Pharm Inc | Méthode de traitement de la cholangite sclérosante primitive |
| CN115137752A (zh) * | 2015-08-25 | 2022-10-04 | Uab研究基金会 | 用于干细胞移植的方法 |
| IL261750B2 (en) * | 2016-03-14 | 2024-07-01 | Millennium Pharm Inc | Method of preventing graft versus host disease |
-
2017
- 2017-03-13 BR BR112018068625A patent/BR112018068625A2/pt not_active Application Discontinuation
- 2017-03-13 KR KR1020187029233A patent/KR102667332B1/ko active Active
- 2017-03-13 JP JP2018548192A patent/JP2019512493A/ja not_active Withdrawn
- 2017-03-13 AU AU2017234010A patent/AU2017234010B2/en active Active
- 2017-03-13 CA CA3017758A patent/CA3017758A1/en active Pending
- 2017-03-13 US US16/084,392 patent/US20190077868A1/en active Pending
- 2017-03-13 MA MA043755A patent/MA43755A/fr unknown
- 2017-03-13 CN CN202310642830.3A patent/CN117298268A/zh active Pending
- 2017-03-13 CN CN201780024678.5A patent/CN109153721A/zh active Pending
- 2017-03-13 MX MX2018011025A patent/MX2018011025A/es unknown
- 2017-03-13 WO PCT/US2017/022067 patent/WO2017160700A1/en not_active Ceased
- 2017-03-13 KR KR1020247016054A patent/KR102830639B1/ko active Active
- 2017-03-13 EP EP17714596.8A patent/EP3430053A1/en active Pending
-
2018
- 2018-09-12 MX MX2024008740A patent/MX2024008740A/es unknown
- 2018-09-13 IL IL261767A patent/IL261767A/en unknown
-
2022
- 2022-06-08 JP JP2022092849A patent/JP2022137024A/ja active Pending
-
2024
- 2024-05-17 AU AU2024203289A patent/AU2024203289A1/en active Pending
-
2025
- 2025-04-10 JP JP2025065073A patent/JP2025118642A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019512493A5 (https=) | ||
| Couriel et al. | A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease | |
| Taylor et al. | Combined effects of calcineurin inhibitors or sirolimus with anti-CD40L mAb on alloengraftment under nonmyeloablative conditions | |
| JP2025118642A (ja) | 移植片対宿主病の処置または予防の方法 | |
| JP2019508448A5 (https=) | ||
| Sgourakis et al. | Corticosteroid-free immunosuppression in liver transplantation: an evidence-based review | |
| Padiyar et al. | Induction antibody therapy in kidney transplantation | |
| JP2022163078A (ja) | 移植片対宿主病予防の方法 | |
| Flinn et al. | Recent advances in graft-versus-host disease | |
| US20250276061A1 (en) | Method and composition for inducing tolerance | |
| Acharya et al. | Anti-thymocyte globulin for treatment of T-cell-mediated allograft rejection | |
| Choi et al. | Uveitis occurrence in patients with ankylosing spondylitis according to the type of tumour necrosis factor inhibitor: a cohort study of 175 patients | |
| JP2024001191A (ja) | 造血細胞移植後の急性移植片対宿主病の発症のリスクを低減する方法 | |
| US20250122289A1 (en) | Methods of treating or preventing graft versus host disease | |
| Warren et al. | Modulating alloimmune responses with plasmapheresis and IVIG | |
| CN1527840A (zh) | Cd25结合分子在类固醇耐受型患者中的用途 | |
| Meijer et al. | Treatment of acute kidney allograft rejection with a non-mitogenic CD3 antibody | |
| US20230073248A1 (en) | Compositions and methods for inducing immune tolerance in transplantation recipients | |
| Russell et al. | Allogeneic transplantation using peripheral blood stem cells | |
| RU2318537C2 (ru) | Применение cd25-связывающих молекул для лечения пациентов, устойчивых к стероидам | |
| Dodd et al. | Renal Transplant Rejection | |
| Busca | The use of monoclonal antibodies for the treatment of graft-versus-host disease following allogeneic stem cell transplantation | |
| Devraj et al. | Impact of Induction Therapy on Clinical Outcomes of Kidney Transplant Recipients: A Single-Centre Cohort Study | |
| Faenza et al. | Hyperimmunized patients awaiting cadaveric kidney graft: is there a quick desensitization possible? | |
| Jain et al. | Inducing all our low risk transplant cadidates: shall we or shall we not |